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Abstract
Background: GSK-3b phosphorylates numerous substrates that govern cell survival. It phosphorylates p53, for example,
and induces its nuclear export, HDM2-dependent ubiquitination, and proteasomal degradation. GSK-3b can either
enhance or inhibit programmed cell death, depending on the nature of the pro-apoptotic stimulus. We previously
showed that the multikinase inhibitor sorafenib activated GSK-3b and that this activation attenuated the cytotoxic effects
of the drug in various BRAF-mutant melanoma cell lines. In this report, we describe the results of studies exploring the
effects of GSK-3b on the cytotoxicity and antitumor activity of sorafenib combined with the HDM2 antagonist MI-319.
Results: MI-319 alone increased p53 levels and p53-dependent gene expression in melanoma cells but did not
induce programmed cell death. Its cytotoxicity, however, was augmented in some melanoma cell lines by the
addition of sorafenib. In responsive cell lines, the MI-319/sorafenib combination induced the disappearance of p53
from the nucleus, the down modulation of Bcl-2 and Bcl-xL, the translocation of p53 to the mitochondria and that
of AIF to the nuclei. These events were all GSK-3b-dependent in that they were blocked with a GSK-3b shRNA and
facilitated in otherwise unresponsive melanoma cell lines by the introduction of a constitutively active form of the
kinase (GSK-3b-S9A). These modulatory effects of GSK-3b on the activities of the sorafenib/MI-319 combination
were the exact reverse of its effects on the activities of sorafenib alone, which induced the down modulation of
Bcl-2 and Bcl-xL and the nuclear translocation of AIF only in cells in which GSK-3b activity was either down
modulated or constitutively low. In A375 xenografts, the antitumor effects of sorafenib and MI-319 were additive
and associated with the down modulation of Bcl-2 and Bcl-xL, the nuclear translocation of AIF, and increased
suppression of tumor angiogenesis.
Conclusions: Our data demonstrate a complex partnership between GSK-3b and HDM2 in the regulation of p53
function in the nucleus and mitochondria. The data suggest that the ability of sorafenib to activate GSK-3b and
alter the intracellular distribution of p53 may be exploitable as an adjunct to agents that prevent the HDM2-
dependent degradation of p53 in the treatment of melanoma.
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Background
Glycogen synthase kinase-3b (GSK-3b) is a constitutively
active kinase regulated primarily by an inhibitory phos-
phorylation at Ser
9 [1] and activated by endoplasmic reti-
cular (ER) and other forms of cellular stress [2,3]. The
enzyme has a variable modulatory effect on the response
to apoptotic stimuli in that it can either enhance or sup-
press apoptosis depending on the nature of the stimulus
[4]. GSK-3b activation, for example, generally inhibits
apoptosis triggered by the engagement of death receptors
[4,5] but enhances the apoptotic response to death signals
originating in the mitochondria [4,6]. GSK-3b activates
NF- B [7] and phosphorylates hexokinase II, facilitating
its association with VDAC [8] in the outer mitochondrial
membrane, both of which would be expected to promote
cell survival. On the other hand, it phosphorylates c-myc,
* Correspondence: dpanka@bidmc.harvard.edu
1Division of Hematology-Oncology, Beth Israel Deaconess Medical Center
and Harvard Medical School, Boston, MA, USA
Full list of author information is available at the end of the article
Liu et al. Molecular Cancer 2011, 10:115
http://www.molecular-cancer.com/content/10/1/115
© 2011 Liu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.b-catenin, and numerous other survival-associated pro-
teins leading to their degradation in the proteasome [9,10],
thereby facilitating programmed cell death.
Among the downstream targets of GSK-3b are the
tumor suppressor p53 and its negative regulator, the E3
ligase HDM2 [2,3,11]. The interaction between these two
proteins is governed largely by the extent to which they
are phosphorylated by upstream kinases. The phosphory-
lation of p53 on any of several serines in its N-terminal
region, for example, prevents its interaction with HDM2
and enhances its stability in response to stress such as
DNA damage or hypoxia [11-15]. N-terminal phophory-
lation also enhances the acetylation of p53 by the acetyl
transferases p300/CBP and PCAF, which facilitates
sequence-specific DNA binding by p53 as well as p53-
dependent transcription [16]. JNK, p38, ATM and ATR
are among the kinases that phosphorylate p53 in this
region and promote its activi t y[ 1 1 ] .T h eC - t e r m i n a l
phosphorylation of p53 by GSK-3b at Ser
315 and Ser
376,
on the other hand, directs the export of p53 from the
nucleus and its subsequent degradation in the protea-
some [2,17,18]. GSK-3b also phosphorylates HDM2,
enhancing its ability to bind and ubiquitinate p53 [8,19].
It is likely that these destabilizing effects on p53 contri-
bute to the prosurvival agenda of GSK-3b in some
circumstances.
p53 mediates cell cycle arrest, senescence, and/or pro-
grammed cell death in response to DNA damage,
hypoxia, and other cellular stresses [20,21]. Although
many of these effects of p53 are attributable to its ability
to promote gene expression, several are due to the
expression of non-coding RNAs or to transcriptional
repression. Although p53 resides primarily in the
nucleus, there is a substantial cytosolic pool of p53 that
in response to an apoptotic stimulus, translocates to the
mitochondria, binds to Bax and Bak directly, and induces
programmed cell death in a manner similar to that
mediated by certain BH3-only members of the Bcl-2
family (i.e. Bim, tBid, and Puma)[22-28]. This particular
function of p53 can trigger the release of cytochrome c
from the mitochondria, the activation of caspases, and
death through a classical apoptotic mechanism. It can
also induce a caspase-independent form of death
mediated by the translocation of Apoptosis-Inducing
Factor (AIF) from the mitochondria to the nuclei. Once
in the nucleus, AIF associates with histone H2AX and
recruits nucleases such as CypA or EndoG, resulting in
the cleavage of DNA into high molecular weight frag-
ments (i.e. programmed necrosis, necroptosis)[29-31].
Both of these mechanisms of programmed cell death are
independent of p53-dependent gene expression.
Recently, several small molecule antagonists of HDM2
have been developed which interfere with the interaction
between p53 and HDM2, resulting in enhanced p53
stability. Most of these small molecule inhibitors (e.g. the
Nutlins, MI-319, and TDP665759) target HDM2 [32-36]
whereas others (e.g. RITA) bind to p53 itself [9,37,38].
Both classes of drug increase p53 levels and p53-depen-
dent gene expression without damaging the genome. In
the absence of HDM2 blockade, GSK-3b activation (in
response to ER stress, for example) leads to the nuclear
export of p53 and its subsequent degradation in the pro-
teasome [2,3]. In the setting of HDM2 blockade, how-
ever, the p53 exported from the nucleus in response to
GSK-3b activation remains available for translocation to
the mitochondria in response to apoptotic signaling. Its
pro-apoptotic function in the mitochondria is further
enhanced by its physical association with GSK-3b [39].
The ability of HDM2 inhibitors to prevent the degrada-
tion of p53 that usually follows its nuclear export and the
ability of GSK-3b to facilitate the redistribution and
mitochondrial function of p53 suggest that combining an
HDM2 antagonist with an agent that activates GSK-3b
might be a particularly useful antitumor strategy.
We previously demonstrated a high degree of variability
in the extent of GSK-3b-Ser
9 phosphorylation among
BRAF
V600E (+) melanoma cell lines and showed that GSK-
3b activity in these cells was increased in response to the
multikinase inhibitor sorafenib [40], presumably through
an ER stress-dependent mechanism. This GSK-3b activa-
tion blocked the down modulation of Bcl-2 and Bcl-xL
and the nuclear translocation of AIF otherwise induced by
sorafenib and limited the toxicity of the drug. In this
report, we show that in the presence of the HDM2 antago-
nist MI-319, sorafenib induces the disappearance of p53
from the nucleus and its translocation to the mitochondria
in melanoma cells. Both of these effects are GSK-3b-
dependent. Although MI-319 alone is minimally toxic in
melanoma cells as a single agent, it amplifies the toxicity
of sorafenib. The cell death elicited by the combination of
sorafenib and MI-319 can be inhibited by pifithrin-μ,a n
agent known to selectively block p53 function in the mito-
chondria without affecting p53-dependent gene expression
[41]. We further show that, in contrast to the suppressive
effect of GSK-3b on the down modulation of Bcl-2 and
Bcl-xL and the nuclear translocation of AIF induced by
sorafenib alone, the ability of the sorafenib/MI-319 combi-
nation to induce these effects requires the participation of
GSK-3b.
The nuclear accumulation of p53 induced by MI-319
alone appears to be well-tolerated by melanoma cells both
in vitro and in vivo. The multikinase inhibitor sorafenib
has been extensively evaluated in melanoma patients both
as a single agent and in combination with chemotherapy
with disappointing results [42,43]. Our data suggest that
the ability of sorafenib to activate GSK-3b and alter the
intracellular redistribution of p53 may be exploitable as an
adjunct to HDM2 blockade in the treatment of melanoma.
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Effects of sorafenib on MI-319-induced cytotoxicity and
p53-dependent gene expression
To assess the effect of sorafenib on MI-319-induced cyto-
toxicity, A375 and SKMEL5 melanoma cells were
exposed to various concentrations of MI-319 and sorafe-
nib for 20 hr, stained with PI, and then analyzed for via-
bility by flow cytometry. The interaction between the two
drugs was evaluated in two studies. In the first, A375 and
SKMEL5 cells were exposed to increasing concentrations
o fM I - 3 1 9i nt h ep r e s e n c e( b l a c kb a r s■) or absence
(white bars □)o f1 0μM sorafenib (Figure 1A) and in the
second, the cells were exposed to increasing concentra-
tions of sorafenib in the presence (black bars ■)o r
a b s e n c e( w h i t eb a r s□)o f1 0μMM I - 3 1 9( F i g u r e1 B ) .A s
shown in Figure 1A, MI-319 had negligible single agent
toxicity for A375 cells and only modest toxicity for
SKMEL5 cells, even at the highest concentration tested
(20 μM). However, in the presence of 10 μM sorafenib,
MI-319 induced a concentration-dependent increase in
PI staining in A375 cells (p < 0.0003, < 0.0023, and <
0.0023 for the drug combination vs. 20 μM MI-319
alone, 10 μM sorafenib alone, and 20 μM sorafenib alone,
respectively). SKMEL5 cells were much more sensitive
than A375 cells to single agent sorafenib but were unaf-
fected by single agent MI-319. Furthermore, the toxicity
of sorafenib in these cells was not appreciably augmented
by the addition of MI-319. As shown in Figure 1B, the
toxicity of single agent sorafenib was concentration-
dependent for both cell lines and in the case of A375
cells, augmented by 10 μM MI-319. MI-319 had no such
enhancing effect on the toxicity of sorafenib in SKMEL5
cells.
To assess the effects of sorafenib on MI-319-induced
p53 accumulation and p53-dependent gene expression,
A375 and SKMEL5 cells were exposed to increasing con-
centrations of MI-319 in the presence or absence of sora-
fenib. As shown in Figure 1C, MI-319 increased p53
levels in A375 and SKMEL5 melanoma cells in a concen-
tration-dependent manner. The expression of the cdk
inhibitor p21
waf was also induced by the drug. The addi-
tion of sorafenib (10 μM) partially inhibited the increase
in p53 levels induced by MI-319 and almost completely
suppressed the expression of p21
waf. Similar data were
obtained in a related experiment in which a fixed concen-
tration of MI-319 (20 μM) was added to varying concen-
trations of sorafenib. As shown in Figure 1D, 10 μM
sorafenib completely inhibited the expression of p21
waf
induced by MI-319 in both cell lines. To verify that sora-
fenib was active as a raf kinase inhibitor, the lysates were
also probed for pERK. Since p21
waf levels can be regu-
lated by ubiquitination and degradation [44,45], we con-
sidered the possibility that the observed effects of MI-319
and sorafenib on p21
waf levels were due to changes in
protein stability rather than p53-dependent gene expres-
sion. To more directly assess the ability of sorafenib to
antagonize MI-319-induced p53-dependent gene expres-
sion, we examined the effects of both drugs on the activ-
ity of a p53-luciferase reporter. As shown in Figure 1E,
p53 reporter activity was induced by MI-319 (p < 0.0041
and < 0.0048 for A375 and SKMEL5, respectively) and
this induction was prevented with sorafenib (p < 0.0060
and < 0.0010 for A375 and SKMEL5, respectively;
MI-319 alone vs. the MI-319/sorafenib combination).
To assess the contribution of p53 to the cytotoxic
effects induced by sorafenib and MI-319, A375 cells were
stably transfected with a tetracycline-inducible p53
shRNA. The transfectants were then treated with doxycy-
cline and evaluated for their susceptibility to MI-319/sor-
afenib-induced programmed cell death as determined by
flow cytometry. As shown in Figure 2A, exposure to dox-
ycycline blocked the induction of p53 and p21
waf by MI-
319, confirming our hypothesis that the increase in
p21
waf levels induced by exposure to MI-319 was p53-
d e p e n d e n ta n dn o tj u s td u et op r o t e i ns t a b i l i z a t i o n
[44,45]. Doxycycline markedly reduced the toxicity of the
MI-319/sorafenib combination (p < 0.0271, Figure 2B),
indicating that the toxicity of the MI-319/sorafenib com-
bination was at least partly p53-dependent.
Effects of sorafenib on the intracellular distribution of
p53: Role of GSK-3b
To determine if the dissociation between p53 levels and
p53-dependent gene expression observed in cells exposed
to sorafenib might be due to a change in the intracellular
distribution of p53, A375 and SKMEL5 cells were
exposed to MI-319 and sorafenib, lysed, and the lysates
fractionated as described in Methods into nuclear and
mitochondrial fractions. Cox-4 and c-myc were used as
markers to assess the purity of the mitochondrial and
nuclear fractions, respectively. As shown in Figure 3A,
exposure to MI-319 markedly increased the amount of
p53 present in the nucleus of both SKMEL5 and A375
cells. The addition of sorafenib, however, prevented this
increase in nuclear p53 and induced the accumulation of
p53 in the mitochondria in A375, but not SKMEL5 cells.
We previously demonstrated that sorafenib activates
GSK-3b [40], a kinase that phosphorylates p53 at two
sites within its nuclear export sequence and regulates its
intracellular distribution [2,3]. The constitutive and sora-
fenib-enhanced activities of GSK-3b were previously
shown to be greater in A375 than in SKMEL5 cells [40].
To assess the role played by GSK-3b in the redistribution
of p53 induced by sorafenib in the setting of HDM2
blockade, we stably transfected A375 melanoma cells
with a tetracycline-inducible GSK-3b shRNA and
SKMEL5 cells with a constitutively active GSK-3b (GSK-
3b
S9A) and examined the response of the transfectants to
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with MI-319 markedly increased the nuclear pool of p53
in all of the transfectants regardless of their GSK-3b sta-
tus. In A375 cells, the addition of sorafenib largely abol-
ished this nuclear accumulation of p53 and induced its
translocation to the mitochondria. Suppression of GSK-
3b by adding doxycycline prevented the redistribution of
p53 induced by sorafenib. The results obtained with
SKMEL5 were comparable to those generated with the
GSK-3b-downmodulated A375 cells and consistent with
the previous observation that SKMEL5 cells have lower
GSK-3b activity than A375 cells [40]. To further impli-
cate GSK-3b activity as a critical determinant of how sor-
afenib affects the intracellular distribution of p53, we
A
E
D B
C
Figure 1 (A and B). Induction of apoptosis in A375 and SKMEL5 cell lines treated with (A) variable concentrations of MI-319 with (black bars) or
without (white bars □)1 0μM sorafenib or with (B) variable concentrations of sorafenib with (black bars) or without (white bars □)2 0μM MI-
319. Data are presented as the percentage of total cells staining positive for propidium iodide. (C and D). p53 and p21
waf levels in A375 and
SKMEL5 cell lines treated with (C) variable concentrations of MI-319 with or without 10 μM sorafenib or with (D) variable concentrations of
sorafenib with or without 20 μM MI-319. (E). p53-luciferase reporter activity in transfected A375 and SKMEL5 cells treated with 10 μM sorafenib
(S) and/or 20 μM MI-319 (M) for 6 hours. Data are presented as fold increase relative to the activity in the untreated control cells.
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cells infected with an adenovirus expressing a constitu-
tively active form of GSK-3b (GSK-3b
S9A). The expres-
sion of the GSK-3b
S9A construct was verified in these
studies by western blot with an antibody to hemaglutinin
(HA). As shown in Figure 3B (lower panel), exposure to
MI-319 increased the nuclear pool of p53 in SKMEL5-
GSK-3b
S9A cells and the addition of sorafenib induced its
disappearance from the nucleus and translocation to the
mitochondria, similar to what was observed in melanoma
cell lines with high constitutive GSK-3b activity such as
A 3 7 5 .A sm e n t i o n e da b o v e ,s o r a f e n i bh a dn oe f f e c to n
the intracellular distribution of p53 in uninfected
SKMEL5 cells. These results indicate that GSK-3b activ-
ity determines that effect of sorafenib on the intracellular
distribution of p53.
We previously showed that the GSK-3b activation
induced by sorafenib exposure was prosurvival in mela-
noma cells in that either the pharmacologic inhibition
or downmodulation of the kinase enhanced sorafenib
toxicity [40]. To determine if the activation of GSK-3b
had a similar protective role in cells exposed to both
sorafenib and MI-319, A375 cells stably transfected with
a tetracycline-regulable GSK-3b shRNA were treated
with 3 μM doxycycline overnight or left untreated and
then exposed to sorafenib and MI-319. The cells were
then stained with PI and analyzed for viability by flow
cytometry. As shown in Figure 3C, the downmodulation
of GSK-3b enhanced the toxicity of single agent sorafe-
nib (as previously reported) but reduced the toxicity of
the sorafenib/MI-319 combination (p < 0.0062 for sora-
fenib/MI-319 with or without doxycycline). These data
suggest that the toxicity of this drug combination is due
to both the increase in p53 levels induced by MI-319
and its mitochondrial translocation, the latter of which
is dependent on the activation of GSK-3b.
Regulation of sorafenib-induced AIF nuclear translocation
by p53 and GSK-3b
We previously demonstrated that sorafenib induced the
mitochondrial release and nuclear translocation of AIF in
melanoma cells sensitive to the drug (e.g. A2058) and that
AIF translocation was responsible for the cytotoxic effects
of sorafenib in these cells [46]. AIF translocation could not
be induced in the more resistant cell line A375. To better
define the roles of GSK-3b and p53 in sorafenib-induced
AIF nuclear translocation, nuclear and mitochondrial frac-
tions were prepared from various drug-treated melanoma
cells and analyzed by western blot for AIF. As shown in
Figure 3B (upper panel), the sorafenib/MI-319 combina-
tion (but not sorafenib alone) was able to induce AIF
nuclear translocation in A375 cells stably transfected with
a tetracycline-regulable GSK-3b shRNA in the absence of
doxycycline. This pattern of AIF translocation, however,
was completely reversed in the presence of doxycycline
(i.e. with GSK-3b down modulated). In the absence of
GSK-3b, sorafenib alone (but not the sorafenib/MI-319
combination) induced AIF nuclear translocation. Data
obtained with SKMEL5 were similar to those obtained
with the GSK-3b-down modulated A375 cells in that sora-
fenib as a single agent induced AIF nuclear translocation
in a setting in which the sorafenib/MI-319 combination
appeared unable to do so. The results obtained with the
SKMEL5-GSK-3b
S9A cells were identical to those obtained
with A375 in that the drug combination, but not sorafenib
alone, induced the nuclear translocation of AIF. These
data are consistent with the ability of GSK-3b activation to
r e d u c et h et o x i c i t yo fs i n g l ea g e n ts o r a f e n i bb u tt o
enhance that of the sorafenib/MI-319 combination.
Role of mitochondrial p53 in MI-319/sorafenib toxicity
To assess the contribution of mitochondrial p53 to the
cytotoxicity induced by the sorafenib/MI-319 combina-
tion, cells were pretreated with pifithrin-μ (10 uM), an
agent that blocks the pro-apoptotic effects of p53 in the
mitochondria without affecting its transcriptional activity
[41]. As shown in Figure 4A, pifithrin-μ pretreatment
reduced the toxicity of the sorafenib/MI-319 combina-
tion by approximately half (p < 0.0267) in A375 cells,
Figure 2 The effect of p53 downmodulation on p21
waf
expression and programmed cell death induced in A375 cells
by the combination of 10 μM sorafenib (S) and 20 μM MI-319
(M). A375 cells expressing a tetracycline-regulable p53 shRNA were
treated with 3 μM doxycycline overnight and then with sorafenib
and MI-319 for 6 hr for the western blots shown in (A) or 24 hours
for the cell death assays shown in (B). Cell death data are presented
as the percentage of total cells staining positive for propidium
iodide.
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action of p53 in cells treated with this drug combination.
To determine if the mitochondrial translocation of p53
was responsible for the nuclear translocation of AIF
induced by sorafenib/MI-319, A375 cells were exposed to
various combinations of sorafenib and MI-319 in the pre-
sence or absence of pifithrin-μ. The cells were then frac-
tionated into nuclear and mitochondrial subsets and
analyzed for AIF by western blot. As shown in Figure 4B,
single agent sorafenib again failed to induce the nuclear
translocation of AIF in A375 cells. The translocation was,
however, readily achieved with the sorafenib/MI-319
combination but could be blocked with pifithrin-μ,s u g -
gesting that it was mediated by mitochondrial p53. Since
the mitochondrial translocation of p53 accounts for
much of the toxicity induced by the sorafenib/MI-319
A
C B
Figure 3 The role of GSK-3b in the redistribution of p53 induced by sorafenib in the setting of HDM2 blockade. (A). Nuclear and
mitochondrial p53 levels in A375 and SKMEL5 cells treated with 10 μM sorafenib (S) and/or 20 μM MI-319 (M). In these studies, c-myc and COX4
were used as markers for the nuclear and mitochondrial subcellular fractions, respectively. (B). (Upper Panel). Nuclear and mitochondrial p53
and AIF levels in A375 cells expressing a tetracycline-regulable GSK-3b shRNA treated with 10 μM sorafenib (S) and/or 20 μM MI-319 (M) with or
without doxycycline pretreatment. The downmodulation of GSK-3b in the doxycycline-treated cells was validated by western blot. (Lower
Panel). Nuclear and mitochondrial p53 and AIF levels in SKMEL5 and SKMEL5-GSK-3b
S9A cells treated with 10 μM sorafenib and/or 20 μM MI-
319. (C). Effect of GSK-3b on the pro-apoptotic effects of single agent sorafenib and the sorafenib/MI-319 combination as determined by flow
cytometry. Cell death data are presented as the percentage of total cells staining positive for propidium iodide.
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activation, we suspected that the suppressive effect of
pifithrin-μ on drug-induced cytotoxicity might be simi-
larly GSK-3b dependent. To test this hypothesis, the
experiments shown in Figure 4A were repeated in addi-
tional melanoma cell lines with variable GSK-3b activity.
As shown in Figure 4C, pifithrin-μ reduced the toxicity
of the sorafenib/MI-319 combination by approximately
half (p < 0.001) in A375 cells stably transfected with a
tetracycline-inducible GSK-3b shRNA in the absence of
doxycycline, similar to its effects on the parent A375 cell
line shown in Figure 4A. Suppression of GSK-3b by the
addition of doxycycline, however, nullified this protective
effect (Figure 4C). Pifithrin-μ also failed to protect
A
C
D
B
Figure 4 Inhibition of the mitochondrial function of p53 with pifithrin-μ diminishes the cytolytic activity of sorafenib/MI-319. (A). Effect
of pifithrin-μ(10 μM) on the apoptotic effects of 10 μM sorafenib (S) and 20 μM MI-319 (M) in A375 cells. Cell death data are presented as the
percentage of total cells staining positive for propidium iodide. (B). Effect of pifithrin-μ on the nuclear translocation of AIF induced by the
sorafenib/MI-319 combination (but not sorafenib alone). c-myc and COX4 were used as markers for the nuclear and mitochondrial subcellular
fractions used in these assays. (C). GSK-3b activity determines whether pifithrin-μ inhibits the cell death induced in melanoma cells by sorafenib
and MI-319. (Left Panel). A375 cells expressing the tetracycline-regulable GSK-3b shRNA with and without doxycycline pretreatment were
treated with sorafenib and MI-319 in the presence or absence of pifithrin-μ. Cell death data are presented as the percentage of total cells
staining positive for propidium iodide. (Right Panel). SKMEL5 and SKMEL5-GSK-3b
S9A cells were treated with sorafenib and MI-319 in the
presence or absence of pifithrin-μ. Cell death data are presented as the percentage of total cells staining positive for propidium iodide. (D).
Effect of MI-319 and sorafenib on PARP cleavage in A375 cells.
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MI-319 unless the constitutively low GSK-3 activity of
these cells was enhanced by the forced expression of
GSK-3b
S9A (p < 0.0212). Collectively, these data establish
a causal link between the activation of GSK-3b, the mito-
chondrial translocation of p53, and the toxicity of the
sorafenib/MI319 combination.
We previously showed that single agent sorafenib
induced the release of cytochrome c but not AIF from the
mitochondria of A375 cells. Sorafenib-induced caspase
activation (PARP cleavage) was delayed in these cells (evi-
dent at only 24 hours) and did not appear to contribute to
the lethality of the drug as the cells were not protected by
the pancaspase inhibitor ZVAD [46]. The combination of
sorafenib with MI-319, on the other hand, readily induced
the translocation of AIF within 6 hours, at which point
PARP was still undetectable (Figure 4D), suggesting that
the early toxicity of this drug combination was caspase-
independent.
Effects of GSK-3b activation and HDM2 blockade on
sorafenib-induced Bcl-2 and Bcl-xL down modulation
As with Bim, tBid, and Puma, the ability of p53 to bind to
and activate Bak and Bax in the mitochondria is limited by
the relative abundance of anti-apoptotic Bcl-2 family
members [22-28]. We previously showed that single agent
sorafenib down modulated Bcl-2 and Bcl-XL in cells with
low constitutive GSK-3b activity (e.g. SKMEL5), but not in
cells with high GSK-3b activity (e.g. A375, SKMEL5-GSK-
3b
S9A) [ 4 0 ] .T od e t e r m i n eh o wG S K - 3 b might affect the
ability of the sorafenib/MI-319 combination to down
modulate these anti-apoptotic BCL-2 family members,
A375-GSK-3b-shRNA cells were exposed to MI-319 and/
or sorafenib and then evaluated for Bcl-2 and Bcl-XL
expression by western blot. As predicted from our earlier
studies with unmodified A375 cells [40], single agent sora-
fenib failed to reduce Bcl-2 and Bcl-xL levels in these
A375 transfectants in the absence of doxycycline or in
SKMEL5-GSK-3b
S9A cells (Figure 5). However, the drug
down modulated these proteins in SKMEL5 cells and
A375 cells in which GSK-3b expression was suppressed by
doxycyline. Exactly the opposite results were obtained
from cells treated with the sorafenib/MI-319 combination.
The combination, for example, induced the down modula-
tion of Bcl-2 and Bcl-XL in A375-GSK-3b-shRNA cells in
the absence of doxycycline and in SKMEL5-GSK-3b
S9A
cells, but not in SKMEL5 or A375 cells in which GSK-3b
expression was down modulated. These results are in
agreement with the data sho w ni nF i g u r e3 B ,w h i c h
demonstrate a similar dichotomous effect of GSK-3b as an
enhancer or inhibitor of AIF nuclear translocation
depending on the status of HDM2. The data shown in
Figure 5 suggest that the mitochondrial translocation of
p53 and the pifithrin-μ-suppressible component of the
toxicity of the sorafenib/MI-319 combination are both
augmented by the GSK-3b-dependent down modulation
of Bcl-2 and Bcl-xL. The data also demonstrate a hitherto
unknown ability of HDM2 activity to determine how
GSK-3b activation (e.g. by sorafenib) affects Bcl-2 and Bcl-
xL expression.
Effects of MI-319 and sorafenib on A375 xenografts
To determine if the antitumor effects of the sorafenib/MI-
319 combination on A375 melanoma cells in vitro could
be reproduced in vivo, A375 melanoma xenografts were
established in nude/beige mice and the mice then treated
Figure 5 GSK-3b activity and p53 levels (HDM2 blockade) determine whether sorafenib exposure downmodulates Bcl-2 and Bcl-xL in
melanoma cells. (Left Panel). A375 cells stably transfected with a tetracycline-inducible GSK-3b shRNA were first treated with doxycycline (or
not) and then exposed to sorafenib and/or MI-319. Cell lysates were then probed for Bcl-2 and Bcl-xL. (Right Panel). SKMEL5 and SKMEL5-GSK-
3b
S9A cells were treated with sorafenib and MI-319 and the cell lysates then probed for Bcl-2 and Bcl-xL.
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dually and in combination. As shown in Figure 6A, the
tumor growth curve from mice treated with MI-319 was
nearly identical to that of the control group. Treatment
with single agent sorafenib had a modest growth-retarding
effect (p < 0.007 for sorafenib vs. control). Treatment with
the drug combination, on the other hand, resulted in a
marked decrease in tumor growth (p < 0.001 for the drug
combination vs. each of the other treatment groups).
To assess the effects of drug treatment on Bcl-2 and
Bcl-xL levels, tumors from the different treatment groups
were excised on day 21 and analyzed by western blot. As
s h o w ni nF i g u r e6 B ,B c l - x L levels appeared to be
increased by treatment with either single agent MI-319
or sorafenib. The protein was undetectable, however, in
the tumors excised from mice treated with the drug com-
bination. A similar pattern was noted for Bcl-2 except
that the baseline levels were lower. Of note, erk phos-
phorylation was not diminished in the tumors from mice
receiving either single agent sorafenib or the sorafenib/
MI-319 combination, indicating that the antitumor effect
of these agents was not the result of raf inhibition.
To assess the mechanism by which the sorafenib/MI-
319 combination impaired tumor growth, tumor tissue
sections were examined by H&E staining for necrosis,
IHC for proliferation (Ki-67) and microvessel density
(CD31), and by TUNEL assay. Routine H&E staining
revealed a marked increase in the extent of necrosis in
tumors from mice treated with either single agent sorafe-
nib or the drug combination Ki-67 staining and TUNEL
assays limited to areas of tumor that were not overtly
necrotic revealed no differences among the treatment
groups (data not shown). Analysis of microvessel density
using antibodies to CD31 showed a statistically signifi-
cant decrease in vascularity in tumors treated with
sorafenib alone relative to controls (p < .024) and an
even greater decrease in vascularity in tumors treated
with the MI-319/sorafenib combination relative to sora-
fenib alone (p < .006) (Figures 7A and 7B).
Histologic sections were also subjected to wide field
immunofluorescence microscopy to assess the intracellular
distribution of p53. As shown in Figure 7C, p53 (red color)
was scarcely detectable in the tumor cells from control or
sorafenib-treated mice. Treatment with single agent MI-
319 resulted in a marked increase in p53, which appeared
to be confined primarily to the nuclei. In the tumor cells
from mice treated with both MI-319 and sorafenib, how-
ever, a substantial amount of p53 was present outside the
nucleus (yellow color) in apparent association with COX4
(green color), consistent with mitochondrial translocation.
Immunofluorescence microscopy was also used to assess
the effect of treatment on the intracellular distribution of
AIF. As shown in Figure 7D (red filter only), AIF was
excluded from the nuclei of tumors excised from control
mice and those treated with either sorafenib or MI-319.
However, AIF was clearly present in the nuclei of tumors
from mice that received both drugs. Figure 7E shows the
same tissue sections with all colors displayed. As shown,
the control and single agent-treated tumors have a promi-
nent yellow to red cytosolic signal that is presumably due
to the proximity of AIF (red) to COX4 (green) in the mito-
chondria. The nuclei (Hoescht stain) appear dark blue in
each of the tumor sections except those from the mice
treated with the drug combination, in which case the blue
color is replaced by violet, indicating AIF nuclear translo-
cation. These data suggest that the antitumor activity of
the sorafenib/MI-319 combination may be due to a direct
apoptotic effect mediated by the p53-dependent mito-
chondrial translocation of AIF as well as an additive anti-
angiogenic effect.
A B
Figure 6 Antitumor effects of sorafenib and MI-319 on A375 melanoma xenografts. (A). Growth curves of A375 xenografts from mice
treated with control vehicle (C), sorafenib (S), MI-319 (M), or both drugs (MS). Data is presented as tumor volume relative to tumor volume
when treatment started. (B). Western blot analyses of whole tumor lysates prepared from tumors excised on day 21.
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Figure 7 (A) Effect of MI-319 and sorafenib on microvessel density in A375 xenografts. Tumors were stained with CD31. A.A
representative tumor section from each treatment group is shown. (B) Endothelial cells were quantitated using Image Pro 6.0 software. Each bar
graph is representative of 6 tumors. (C). Immunofluorescence microscopic evaluation of p53 (red) in tumor cells from A375 xenografts. Drug
treatment was as indicated in the figure. COX4 (green) was used as a mitochondrial marker in this study. (D). Immunofluorescence microscopic
evaluation of AIF (red) in tumor cells from A375 xenografts. Drug treatment was as indicated in the figure. (E). Immunofluorescence microscopic
evaluation of AIF in tumor cells from A375 xenografts. All colors are shown here (i.e. blue = Hoescht (Bisbenzimide H33342) stain, green = COX4,
AIF = red). Drug treatment was as indicated in the figure.
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Although the HDM2 antagonist MI-319 failed to induce
an increase in PI-staining, AIF nuclear translocation, or
any other manifestation of programmed cell death in
melanoma cells when used as a single agent, it was mark-
edly toxic in some (e.g. A375), but not all, melanoma cell
lines when used in conjunction with the multikinase inhi-
bitor sorafenib. The cytotoxic effect of the MI-319/sora-
fenib drug combination in responsive melanoma cells
appears to depend on p53 acting in the mitochondria, an
effect determined primarily by the GSK-3b activity of the
cell line. Our data indicate that GSK-3b activity is not
only required for the drug combination to induce the
mitochondrial translocation of p53 but also the down
modulation of Bcl-2 and Bcl-xL and the nuclear translo-
cation of AIF. The critical role played by GSK-3b in these
events contrasts with the largely inhibitory function of
the kinase on these parameters when sorafenib is used as
as i n g l ea g e n t .I nt h ea b s e n c eo fH D M 2b l o c k a d e ,f o r
example, exposure to sorafenib induced the down modu-
lation of Bcl-2 and Bcl-xL and the nuclear translocation
of AIF only in cells with low GSK-3b activity.
An alternative way of presenting these data would be
point out that sorafenib is able to down modulate Bcl-2
and Bcl-xL and induce AIF nuclear translocation in cells
with low GSK-3b activity only when HDM2 is functional
and that HDM2 blockade inhibits these effects. HDM2
blockade, on the other hand, is essential for sorafenib-
induced Bcl-2 and Bcl-xL down modulation and AIF
nuclear translocation in cells with high constitutive GSK-
3b activity.
The basis for these context-dependent effects of HDM2
and GSK-3b on the cytotoxicity of sorafenib is unknown
but several potential mechanisms may be operative. The
cleavage of AIF from the inner mitochondrial membrane
prior to its release, for example, is mediated by calpain
and this proteolytic event is enhanced by oxidative modi-
fication of AIF by ROS [47]. The generation of ROS is
regulated by the transcription factor Nrf2, whose activity
is in turn enhanced by an association with p21
waf [48]. In
cells with low GSK-3b activity, p53 remains largely
nuclear and it is therefore conceivable that in these cir-
cumstances the increase in p21
waf induced by MI-319
limits ROS production and the processing and subse-
quent release of AIF from the mitochondria.
In cells with high GSK-3b activity, HDM2 blockade
enhances the ability of sorafenib to induce AIF nuclear
translocation and to down modulate Bcl-2 and Bcl-xL.
There are several mechanisms by which p53 and GSK-3b
could collaborate to achieve this effect. For example,
GSK-3b is known to phosphorylate CREB, b-catenin, c-
myc, and other transcriptional factors that regulate Bcl-2
and Bcl-xL expression [1,4,49,50]. Once phosphorylated
by GSK-3b, these transcriptional factors become
substrates for p53-regulated E3 ligases such as b-TrCP or
FBW7 [51-53] and are polyubiquitinated and degraded in
the proteasome. It is therefore possible that GSK-3b and
a p53-inducible E3 ligase work in tandem to destabilize
these transcription factors, resulting in the reduced
expression of Bcl-2 and Bcl-xL.
Using drug doses that have been previously reported
for other xenograft models (see Materials and Methods),
MI-319 as a single agent appears to be completely inef-
fective at constraining the growth of A375 xenografts
and sorafenib has only a modest effect. The two drugs
together, however, markedly delay tumor growth. The
growth suppression induced by the drug combination is
associated with many of the biochemical changes
observed in vitro in A375 cells including the down modu-
lation of Bcl-2 and Bcl-xL, the mitochondrial transloca-
tion of p53, and the nuclear translocation of AIF. In
addition, the vascularity of xenografts from mice treated
with MI-319 and sorafenib was decreased relative to that
of mice treated with sorafenib alone, which was in turn
decreased relative to controls. Since the reduced vascu-
larity of the sorafenib groupw a sn o ta s s o c i a t e dw i t ha
demonstrable retardation in tumor growth, it is unclear
whether enhanced suppression of angiogenesis resulting
from the addition of MI-319 accounts for the superior
anti-tumor activity of the combination.
Conclusions
The multikinase inhibitor sorafenib has been extensively
evaluated in melanoma patients both as a single agent and
in combination with chemotherapy with disappointing
results. Our data suggest that the ability of sorafenib to
activate GSK-3b and alter the intracellular redistribution
of p53 may be exploitable as an adjunct to HDM2 block-
ade in the treatment of melanoma. Our data suggest that
the high p53 levels inducible in melanoma cells with an
HDM2 antagonist may not result in programmed cell
death in vitro or appreciable tumor regression in vivo
unless the drug is administered in conjunction with a sec-
ond agent that can facilitate these GSK-3b-dependent
cytotoxic effects. The ability of HDM2 inhibitors to pre-
vent the degradation of p53 that usually follows its nuclear
export and the ability of GSK-3b to facilitate the redistri-
bution and mitochondrial function of p53 suggest that
combining an HDM2 antagonist with an agent that acti-
vates GSK-3b might be a particularly useful antitumor
strategy.
Materials and Methods
Cell lines and reagents
The human melanoma cell lines A375 and SKMEL5 were
obtained from ATCC and maintained in RPMI-1640
medium containing 10% fetal bovine serum (USA Scien-
tific), 2 mM glutamine and 50 μg/ml gentamycin at 37°C
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for the constitutively active BRAF
V600E mutation [54]
while the A375 line is homozygous as determined by
sequence analysis. Sorafenib was provided by Bayer Phar-
maceuticals, New Haven, CT. The MI-319 was provided
by Ascenta Therapeutics (Malvern, PA) and Sanofi-Aven-
tis (Paris, France).
Western blots
Cells were treated as described in Results and then lysed in
Lysis Solution (Cell Signaling) supplemented with sodium
fluoride (10 μM, Fisher Scientific, Hampton, NH) and phe-
nylmethylsulfonyl fluoride (100 μg/ml, Sigma-Aldrich, St
Louis, MO). Lysates were fractionated in 8-16% gradient
SDS-polyacrylamide gels as indicated and the separated
proteins were transferred to nitrocellulose. The blots were
probed for the proteins of interest with specific antibodies
followed by a second antibody-horse radish peroxidase
conjugate and then incubated with SuperSignal chemilu-
minescence substrate (Pierce, Rochford, IL). The blots
were then exposed to Kodak X-Omat Blue XB-1 film. The
p21, phospho-p53 (Thr
55), Bcl-xL and AIF antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz,
CA); the phospho-erk, c-myc, Bcl-2, p53, phospho-p53
(Ser
315), Bax, HA-tag, PARP and GSK-3b antibodies were
purchased from Cell Signaling (Beverly, MA). The Bak
antibody was from Calbiochem (San Diego, CA). The vin-
culin antibody was obtained from Sigma (St. Louis, MO);
the COX4 antibody was obtained from ABCAM (Cam-
bridge, MA).
Cell death assays
In each of these assays, the adherent cells were detached
from the underlying plastic by treatment with trypsin/
EDTA in PBS for 5 minutes and then combined with the
floating, nonadherent cells. Propidium iodide (PI, 5 ng/ml,
Sigma) was added to the cell pool and after 20 minutes at
room temperature, the cells were analyzed by flow cyto-
metry with a BD Biosciences FACScan. The percentage of
cells staining with propidium iodide (PI) was recorded and
each experiment reported was carried out at least 3 times.
Data were reported as the mean +/- standard error for
each experimental condition. In each of these assays, the
percentage of cells staining with PI was taken to represent
the extent of cell death induced by the experimental con-
dition being tested.
p53 reporter assay
A p53 reporter vector containing the p53 response ele-
ment coupled to firefly luciferase was purchased from
Stratagene (Agilent Technologies, Santa Clara, CA).
Briefly, tumor cell lines were transfected with the p53 luci-
ferase and a CMV renilla luciferase vector (a gift of
Stephen Balk, BIDMC) using Superfect (Qiagen) following
the manufacturer’s protocol. Twenty-four hours later, the
cells were treated with sorafenib (10 μM) and MI-319
(20 μM) for 6 hours. The lysates were assayed using the
Dual-Luciferase Reporter Assay System from Promega
Corporation (Madison, WI). The data are presented as the
ratio of firefly to renilla luciferase activity normalized to
untreated controls.
Subcellular fractionations
Mitochondria-enriched and cytosolic fractions were iso-
lated from Dounce-homogenized cells using the ApoAlert
Cell Fractionation Kit (BD Clontech). The quality of
the mitochondria-enriched fractions was validated by Wes-
tern blot using an antibody for the mitochondrial protein
cytochrome c oxidase subunit IV (COX4) [55]. Cytosolic
fractions were obtained during the isolation of the mito-
chondria. Nuclei were isolated according to a standard pro-
tocol [56], lysed, and analyzed by western blot.
Design and construction of genetically modified
melanoma cell lines
The generation of SKMEL5 cells expressing a constitu-
tively active GSK-3b was previously described [40]. To
generate the p53 and GSK-3b shRNA transfectants,
the shRNA sequence selector and shRNA hairpin oligonu-
cleotide sequence designer software provided by BD Clon-
tech was used to select optimal sequences. Three shRNAs
were generated for each gene to be silenced. To produce
tetracycline-regulable shRNAs, the oligonucleotides
selected were cloned into the pSingle-tTS-shRNA vector
(BD Clontech). This vector is a tet-on vector. The three
shRNA constructs were transfected as a group into A375
cells and stable transfectants obtained by selection in
G418. Clones were screened individually for inducible
expression of the shRNA (i.e. the downmodulation of the
gene of interest as determined by Western blot) and 2-3
representative clones were selected for each shRNA based
on the degree to which tetracycline exposure suppressed
the expression of the gene of interest.
Immunoprecipitation experiments
Immunoprecipitations were carried out using a Protein
A Immunoprecipitation Kit purchased from Roche Diag-
nostics (Mannheim, Germany). Briefly, treated cells were
lysed and subjected to Dounce homogenization, fol-
lowed by a pre-clearing step with protein A-sepharose.
The cleared lysates were incubated with 10 μgp r i m a r y
antibody for 3 hours at 4°C, followed by an overnight
incubation with protein A-sepharose. After washing
with increasingly stringent buffers, the immunoprecipi-
tated proteins were subjected to western blot analysis as
described above.
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All animal studies were conducted according to Animal
Investigation Committee (AIC)-approved protocol of
Beth Israel Deaconess Medical Center. Six to eight week
old athymic nude/beige female mice (Charles River Labs)
were implanted subcutaneously with 1.0 × 10
7 A375 mel-
anoma cells. When the tumors reached 7-8 mm in dia-
meter, the mice were divided into 4 treatment groups of
6 mice each and treated daily for 21 days by gavage with
sorafenib (80 mg/kg), MI-319 (200 mg/kg), sorafenib +
MI-319, or saline (control). The doses of sorafenib
[57,58] and MI-319 [59,60] were as previously reported.
Tumors were measured bidimensionally daily. Tumor tis-
sue from the sacrificed mice was frozen in liquid N2 for
western blot analysis as described in Results or fixed in
formalin for paraffin embedding.
Immunohistochemistry and immunofluorescence
microscopy
The paraffin-embedded tumor tissue was sectioned at 5
microns using a Leica RM 2125 rotary microtome. The
sections were dewaxed at 60°C, serially immersed in solu-
tions of decreasing alcohol concentration, and then
boiled in 10 mM sodium citrate, pH 6.2, for 30 minutes
to unmask antigens. The tissue was then incubated in 3%
hydrogen peroxide for 5 minutes, blocked with 1% BSA
and 5% goat serum, and incubated overnight at 4°C with
an antibody to Ki-67 (Dako, Carpinteria, CA). The Ki-67
epitope was detected using a biotinylated anti-mouse Ig
antibody and an avidin-horseradish peroxidase conjugate
(Vector Laboratories, Burlingame, CA). Similarly, sec-
tions were stained for endothelial cells with an antibody
to CD 31 (ABCAM), followed by a biotinylated anti-rab-
bit Ig antibody (Vector Laboratories, Burlingame, CA).
Slides were then counterstained with hematoxylin, dehy-
drated, and mounted.
The sections were assayed for apoptosis using the
TUNEL method (Millipore, Billerica, MA) in accordance
with an established protocol [61]. The tissue was
hydrated and treated sequentially with proteinase K and
hydrogen peroxide, and then blocked as described above
for the Ki-67 staining. The sections were then exposed to
a solution containing mixed nucleotides, some of which
were digoxygenin-labeled, and terminal deoxynucleotidyl
transferase (TdT). The slides were developed with an
anti-digoxigenin antibody-peroxidase conjugate and DAB
substrate. Tissue staining was quantitated using IMAGE
Pro 6.0 software (MediaCybernetics, Inc, Bethesda, MD).
Immunofluorescence microscopy was utilized to assess
the translocation of p53 and AIF to the nuclei and mito-
chondria, respectively. For p53, the above protocol for
IHC was followed using a COX 4 antibody conjugated to
Alexa 488 (green) and a p53 antibody conjugated to
Alexa 555 (red) (both from Cell Signaling, Danvers, MA).
For AIF staining, a primary AIF rabbit antibody was used
(Santa Cruz) followed by a secondary antibody to rabbit
IgG conjugated to Alexa 555, along with the COX 4 anti-
body-Alexa 488 conjugate. Finally, nuclei were stained
with Bisbenzimide H33342 (Alexis Biochemicals, San
Diego, CA). Immunofluoresence microscopy was carried
out with a Nikon TE-2000E microscope at 100X magnifi-
cation and a Hamamatsu Orca ER camera. The data was
acquired with Nikon’s NIS-Elements and analyzed with
ImageJ software.
Statistical analysis
In vitro data depicted as bar graphs represent mean values
from at least 3 separate experiments +/- standard error.
For most of the studies shown, the significance of an
apparent difference in mean values for any parameter (e.g.
the percent of cells staining with propidium iodide) was
validated by a Student’s unpaired t test and the difference
considered significant if p < 0.05. For the xenograft stu-
dies, the growth curves of the different treatment groups
were statistically compared using one-way ANOVA.
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